The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
A new federal rule strengthens prohibition on insurers and health plans putting greater limits on access to behavioral health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results